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Background: To assess the dosimetric effect induced by inter-observer variability in target definition for
3D-conformal RT (3DCRT) and volumetric modulated arc therapy by RapidArc (RA) techniques for rectal cancer
treatment.
Methods: Ten patients with rectal cancer subjected to neo-adjuvant RT were randomly selected from the internal
database. Four radiation oncologists independently contoured the clinical target volume (CTV) in blind mode.
Planning target volume (PTV) was defined as CTV + 7 mm in the three directions. Afterwards, shared guidelines
between radiation oncologists were introduced to give general criteria for the contouring of rectal target and the
four radiation oncologists defined new CTV following the guidelines. For each patient, six intersections (I) and
unions (U) volumes were calculated coupling the contours of the various oncologists. This was repeated for the
contours drawn after the guidelines. Agreement Index (AI = I/U) was calculated pre and post guidelines. Two RT
plans (one with 3DCRT technique using 3–4 fields and one with RA using a single modulated arc) were optimized
on each radiation oncologist’s PTV. For each plan the PTV volume receiving at least 95% of the prescribed dose
(PTV V95%) was calculated for both target and non-target PTVs.
Results: The inter-operator AI pre-guidelines was 0.57 and was increased up to 0.69 post-guidelines. The maximum
volume difference between the various CTV couples, drawn for each patient, passed from 380 ± 147 cm3 to 137 ±
83 cm3 after the introduction of guidelines. The mean percentage for the non-target PTV V95% was 93.7 ± 9.2%
before and 96.6 ± 4.9%after the introduction of guidelines for the 3DCRT, for RA the increase was more relevant,
passing from 86.5 ± 13.8% (pre) to 94.5 ± 7.5% (post). The OARs were maximally spared with VMAT technique while
the variability between pre and post guidelines was not relevant in both techniques.
Conclusions: The contouring inter-observer variability has dosimetric effects in the PTV coverage. The introduction
of guidelines increases the dosimetric consistency for both techniques, with greater improvements for RA
technique.
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Modern radiation therapy techniques with inverse
planning optimization are able to achieve optimal dose
painting covering any desired volume. In this context
accurate target delineation is vitally important to en-
sure that the target is not under-treated and to limit
the dose to surrounding normal tissues. At this pur-
pose, recent reports recommended the creation of a
target definition consensus and stated the importance
of specific educational interventions concerning target
contouring.
Pre-operative chemo-radiotherapy of rectal cancer in
locally advanced stage has become a widely accepted
treatment modality. Locally advanced rectal cancer
treated with neo-adjuvant chemoradiation therapy is
expected: a) to show positive response with tumour
down-staging in about half of patients [1]; b) to obtain
better results in terms of local control compared to ad-
juvant approach as shown in a phase III study [2]. The
new technologies in radiotherapy, such as intensity
modulated radiotherapy (IMRT) or more recently volu-
metric modulated arc therapy (VMAT), allow to achieve
highly conformed dose distribution on the target vol-
ume and to spare the adjacent healthy tissues (HT) and
organs at risk (OAR). In several studies with patients re-
ceiving pelvic irradiation for rectal or anal cancer, it has
been shown that IMRT and VMAT are dosimetrically
superior to other conformal techniques in protecting
normal tissue close to the target [3]. Roberton et al. [4]
showed dose-volume relationship between bowel irradi-
ation and acute grade 3 diarrhoea to be clearly corre-
lated and suggested the need of reducing as much as
possible the OARs involved in preoperative irradiation
of rectal cancer. Thus a contouring methodology shared
by the group is a fundamental topic, as assessed by
many works on rectal cancer [5-8].
In this paper we have investigated the dosimetric
impact of introducing educational interventions in the
delineation of the rectal target. We conducted a study
in which participating radiation oncologists delineated
target contours before and after the introduction of
shared guidelines. The aim of the study was to evaluate
and compare the dosimetric effects of target contouring
variability in cases of 3Dconformal RT (3DCRT) and of
RapidArc (RA) techniques. Plans were optimized for
each target delineated by the radiation oncologists. The
primary endpoint was to evaluate the dosimetric cover-
age of the remaining radiation oncologist’s targets
defined on the same patient. Secondary endpoint was
the evaluation of doses at OAR for the two techniques.
The contouring inter-observer variability within the
radiation oncologists of the group before and after the
introduction of shared guidelines was preliminarily
evaluated.Methods
Patient selection
Ten patients (seven males and three females) with
pathologically proven rectal cancer in locally advanced
stage, subjected to neo-adjuvant RT with curative intent
were considered in the present analysis. Patients were
randomly selected from the internal database of patients;
to avoid possible biases in contouring, the patients’
names were hidden and associated with a progressive
numeration. Computed tomography (CT) datasets were
acquired with a 3-mm slice thickness from a 16 slice CT
system, in free breathing condition. Patients, with arms
raised above the neck, were in prone position and
immobilized with Belly-Board devices to dislocate anteri-
orly as much as possible intestinal loops of small bowel.
Four radiation oncologists were involved in this study.
Each of them was asked to contour the clinical target
volume (CTV) for each of the ten patients in blind mode
(i.e. radiation oncologists could not see the contours of
the other oncologists involved in the study). After that,
our institute’s rectal cancer referential radiation oncolo-
gist established a consensus-based guideline on CTV de-
lineation, in order to share some general criteria for the
contouring of rectal target. After a minimum of one
month, the same four radiation oncologists contoured
the ten targets following the guidelines, in blind mode,
too (i.e. radiation oncologist’s could not see neither the
other physician’s contours nor their own previous ones).
The planning target volume (PTV) was defined adding
three-dimensional 7 mm margins to the CTV.
Target definition guidelines
This educational intervention included a formal guideline,
available on-line in our department, as well as an initial
teaching session involving all physicians taking part to this
study. The CTV had to include the entire mesorectum,
the presacral and internal iliac nodal regions, the gross
tumor with a cranial and caudal margin of at least 2 cm.
Criteria for CTV delineation strictly followed guidelines
from Roels et al. [6]. Since RTOG atlases are commonly
used in our department by means of on-line links at the
contouring workstations, participants were carefully in-
formed about differences of our criteria compared with
those in the RTOG paper from Myerson et al. [5].
Planning techniques
For each patient, 8 plans (4 3DCRT and 4 RA) were opti-
mized before the introduction of the guidelines and other
8 were optimized after the guidelines introduction. Each
PTV drawn by the four physicians before and after the
guidelines introduction was set as plan target of one of the
16 plans optimized for each patient. A standard protocol
was adopted for all plans: dose prescription was set to 50.4
Gy to mean PTV in fractions of 1.8 Gy/day. For all PTVs,
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PTV volume must be covered by 95% of the prescribed
dose) and a maximum dose (i.e. D2% as defined in ICRU
83) lower than 107%. Bowel (defined as the entire periton-
eal cavity), bladder and femoral heads were considered as
OARs. The mean dose, maximum dose (D2%) and appro-
priate values of V ×Gy (volume receiving at last × Gy)
were scored. Planning objectives for OARs were defined
as follows: bowel V45Gy < 80 cm
3 and V50Gy < 20 cm
3; no
hotspot inside the bladder was allowed, D30% < 35 Gy, and
mean dose objective was <45 Gy; femoral heads maximum
dose (D2%) < 47 Gy [3]. The planning objectives for HT
were not numerically formalised, the strategy was to min-
imise its involvement.
The 3DCRT series were planned according to our insti-
tute’s practice with three fields (one posterior and two lat-
erals with wedges) or four fields (posterior, anterior, and
two laterals with wedges) with 6 MV or 18 MV energy.
The beam arrangement was set in order to obtain the best
solution according to the target shape. Conformal shaping
of the fields was performed by means of static MLC, set-
ting 5 mm MLC margin in lateral and 7 mm in cranial-
caudal direction. The RA plans consisted of a single
360° arc of 6 MV; the RA plans were optimized starting
with a common dose volume histogram (DVH) object-
ive template. All plans were normalized to the mean
dose of the target PTV (i.e.100% at target mean). Both
techniques were optimized using Varian Eclipse treat-
ment planning system (version 8.9) on a 2100-DHX
Varian Linac, equipped with a Millennium MLC (leaf
width at isocentre of 5 mm in the central 20 cm part of
the field, 10 mm in the outer 2 × 10 cm and a leaf trans-
mission of 1.7%). All dose distributions were computed
with the Anisotropic Analytical Algorithm (AAA) im-
plemented in the Eclipse planning system with a calcu-
lation grid resolution of 2.5 mm.
Data analysis
Firstly, the contours were evaluated from the geomet-
rical point of view. In particular, for each patient the
CTV volumes were measured and the variation was cal-
culated as the maximum volume difference between two
CTVs among the four targets (one for each physician)
drawn on a same patient. The percentage volume vari-
ation was calculated for each patient’s target, defined as
Δ = 100 × (Vmax–Vmin)/Vmean. Furthermore the ratio
(Vmax/Vmin) was reported. These definitions were used
to give information about the deviation regardless of the
volume absolute values. Concerning the interobserver
contouring variability, for each patient six intersections
(I) and unions (U) volumes were calculated coupling the
contours of the various oncologists. This was repeated
for the contours drawn after the guidelines. Agreement
Index (AI) (i.e. with Vi and Vj the volume delineated bythe i-th and j-th physician) AI ij¼ V i∩V jV i∪V j was calculated for
each target and for all possible couples of contours pre
and post guidelines introduction.
Quantitative evaluation of plans was performed by
means of DVH. For PTV the following data were
reported and used as a parameter: target coverage evalu-
ating the PTV V95%: PTV’s volume receiving at least
95% of the prescribed dose (dose prescription: 50.4 Gy).
These parameters were evaluated separately for the target
PTV (i.e. the PTV on which the plan was optimized) and
for non-target PTVs (see Figure 1) in order to assess the
dosimetric impact of the target definition uncertainty
for both the techniques considered. This analysis was
performed before and after the introduction of guidelines
in order to evaluate a possible dosimetric improvement.Study design and statistical analysis
The present study was performed as part of the internal
quality process for improving RT practice. Ten CT scans
were considered as a representative sample of the pro-
cedure. Contours and plans were compared with the
Wilcoxon matched-pair signed-rank test for non-
parametrically distributed data. The threshold for statis-
tical significance was set at p < 0.05. The analysis was
performed using Statistica 6.0 (Vigonza, Italy).Results
Contouring inter-observer variability
A total of 80 contours were generated and analyzed.
Each contour was superimposed on the original CT im-
ages. An example of target contouring drawn before and
after the introduction of guidelines by the four radiation
oncologists is shown in Figure 2.
Tables 1 and 2 report the analysis of the CTV volumes
contoured before and after the guidelines introduction.
In detail, the mean inter-operator variability, evaluated
on CTV contouring, was evaluated before and after the
introduction of the guidelines. For the pre-guidelines con-
tours, mean CTV volume was 380 cm3 ranging from a
maximum of 682 cm3 (patient 2) to a minimum of 117 cm3
(patient 7) and the mean value decreased to 137 cm3
ranging from 283 cm3 (patient 10) to 31 cm3 (patient 4)
for the post guidelines contours. The ratio of the largest to
the smallest contoured volume was 1.79 before and 1.27
after the introduction of guidelines. The inter-operator AI
passed from 0.57 to 0.69 thanks to the guidelines intro-
duction. The intra-observer AI before and after the guide-
lines introduction was 0.74, with significative target
volume reduction.
The most relevant discrepancy in terms of target def-
inition regarded the bilaterally inclusion of external iliac
nodes. This differences influenced the anterior posterior
Figure 1 A schematic representation of the PTV analysis is presented: the four physicians defined four different targets on the same
patient, for each patient four plans were optimized on the different PTVs. During the DVH evaluation the PTV on which the target was
optimized was called target PTV, while the other targets present on the same CT series were called non-target PTVs. Obviously all targets were
both target and non-target PTVs according to the plan considered. This procedure was performed for each patient and for the two planning
techniques (3DCRT and RA) before and after the introduction of the guidelines.
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vant differences were found (<1 cm).
Target coverage and dose homogeneity
Figure 3 shows representative examples of dose distribu-
tions, using color-wash lookup table, obtained with both
3DCRT and RA techniques on the same patient. Plans
on the left were optimized on the PTV defined by physi-
cians 1 while plans on the right were optimized on the
target drawn by physician 2 before the introduction of
the guidelines. The target PTVs were fully covered both
with 3D-CRT and RA though RA technique allows a bet-
ter dose sculpting on the target and a dose reduction on
neighbour HT. This dose sculpting, however, induces an
under dosage on the non-target PTV (i.e. the PTVsFigure 2 Four different contours of CTVs superimposed on a
axial section of a CT image pre (left) and post (right) the
introduction of guidelines.delineated by the other physician on the same patient)
for both plans (see arrows in Figure 3). On the contrary,
the 3D-CRT, with the classical box approach, has a lower
sparing of the neighbor tissue but allows a better cover-
age of the non-target PTVs, and only in one case indu-
cing an under-dosage.
Figure 4 shows the PTVs drawn by physicians 1 and 2
(the same of Figure 3) after the introduction of the
guidelines. Dose distributions, using color-wash lookup
table, are shown. As a consequence of the shared guide-
lines, the contours appear more similar and thus the
dose distributions too; in this case, only a small area of
the non-target PTV was not covered using the RA ap-
proach, while a complete coverage was met for the
3DCRT technique.
Table 3 reports the systematic DVH analysis for the
3DCRT and RA techniques before and after the guide-
lines introduction. Data in the table are normalized to
the prescription dose (100% corresponds to 50.4 Gy). In
detail, the target PTV always fulfilled the objectives in
terms of target coverage (95% of the volume received
95% of the prescribed dose). Considering the non-target
PTVs, instead, the mean volume receiving 95% of the
prescribed dose was 93.7 ± 9.2% before and 96.6 ± 4.9%
after the introduction of guidelines for the 3DCRT; for
RA plans the increase was more relevant, going from
Table 1 Analysis of the CTVs volume contouring pre and













1 745 336 [656; 992] 45 1.51
2 772 682 [528; 1210] 81 2.08
3 545 494 [380; 874] 91 2.30
4 499 467 [366; 833] 94 2.28
5 540 302 [415; 716] 56 1.73
6 463 248 [330; 578] 54 1.75
7 559 117 [494; 611] 21 1.24
8 722 307 [618; 925] 43 1.50
9 648 480 [486; 966] 74 1.99
10 994 423 [790; 1213] 43 1.54
Mean 649 380 - 60 1.79
St Dev 162 147 - 24 0.36











1 797 98 [848; 750] 12 1.13
2 666 254 [771; 518] 38 1.49
3 496 136 [565; 429] 27 1.32
4 400 31 [417; 386] 8 1.08
5 483 40 [504; 465] 8 1.09
6 406 153 [483; 331] 38 1.46
7 502 168 [574; 406] 33 1.41
8 608 79 [642; 564] 13 1.14
9 574 132 [635; 503] 23 1.26
10 1019 283 [1174; 891] 28 1.32
Mean 595 137 - 23 1.27
St Dev 192 83 - 12 0.15
Median 538 134 - 25 1.29
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percentage of plans that had an acceptable non-target
PTV coverage (i.e. V95% ≥ 95%) passed from 62% to 73%
(+11%) for 3D-CRT, while for VMAT plans the increase
was +22% (from 41% to 63%) (see Figure 5).
For OARs the results were the following: for the blad-
der V40Gy = 41.1 ± 24.8% for 3D pre, 23.7 ± 20.1% for RA
pre, 29.7 ± 18.7% for 3D post and 16.0 ± 10.7% for RA
post; the mean dose for right and left femur resulted
almost equivalent: 32 Gy for 3D pre, 30 Gy for 3D post
and 19 Gy for RA pre and post guidelines.
The mean values of MU/Gy for 3D plans were 179.2 ±
17.2 and 180.4 ± 6.8 respectively for pre and postguidelines, while for RA plans these values were 198.6 ±
26.2 and 187.3 ± 18.3 for pre and post guidelines plans
respectively.
Discussion
This work is located inside the topic of quantifying and
improving the precision and accuracy of the RT treat-
ments with an interdisciplinary approach, as summarized
by Yorke at al. in the anniversary paper on the role of
medical physicists in improving geometric aspects of treat-
ment accuracy and precision [9]. Imprecise localization of
internal anatomy, tissue in-homogeneities, patient volun-
tary and involuntary motions, and other kind of human
induced uncertainties can lead to inaccuracies much
greater than the 1–2% of the usual absolute dose calibra-
tion uncertainty. In this report the dosimetric conse-
quences of inter-observer variability in target contouring
for different techniques was evaluated. The rectal tumor
case was chosen as representative of challenging target
definition and for its concave shape, very suitable for
intensity modulated techniques.
Inter-observer variability in target volume delineation is
demonstrated to be one of the major factors contributing
to the global uncertainty in radiation treatment planning
[7,8,10]. Accurate target delineation is extremely import-
ant to make sure that the CTV is not under-treated and to
limit the dose to surrounding normal tissue. Despite the
well-known consequences of geometric inaccuracy in
target volume delineation [11-13], variability in target
delineation has been demonstrated in several studies and
for various anatomic tumor sites [13]. In the case of non-
small cell lung cancer, for example, Steenbakkers et al.
[14] reported that the size of GTV ranged from 36 cm3
to 129 cm3 (ratio 3.6, average 69 cm3), while van
Sornsen de Koste et al. [15] found that the average
GTV for the main tumor of a cT2N2M0 lung cancer
was 13.6 cm3 (SD 5.2 cm3, median 12.3 cm3, range 8.3-
26.9 cm3) as determined by 16 radiation oncologists.
Concerning rectal cancer, CTV delineation presents a
great variability in literature. Fuller et al. [7] analyzed a
set of patients very similar to the ones in this study in
terms of tumor stage and found a range in CTV delin-
eation between 590 cm3 and 820 cm3; this result is com-
parable with our findings (CTV range between 499 cm3
and 994 cm3). The impact of the uncertainties should
be evaluated again whenever a new modality of treat-
ment delivery is introduced in the clinical practice and
for RA this evaluation was already performed from
other points of view [16,17]. This is particularly import-
ant since an increase in precision and conformation of
dose distribution usually leads to heavier effects on dose
distribution due to geometric uncertainties.
In this study we have evaluated the dosimetric impact
of introduction of shared guidelines in the contouring of
Table 2 Results from the analysis of the Agreement Index
Agreement Index (I/U)_Pre-Guidelines
I_Tot/U_Tot 1 vs 2 1 vs 3 1 vs 4 2 vs 3 2 vs 4 3 vs 4
Mean; 0.39 0.60 0.62 0.66 0.58 0.55 0.60
[min; max] [0.27; 0.51] [0.48; 0.76] [0.44; 0.73] [0.53; 0.78] [0.44; 0.70] [0.42; 0.65] [0.50; 0.74]
St. Dev 0.08 0.08 0.10 0.07 0.08 0.08 0.09
Err% 20.7 13.6 15.9 10.2 14.0 14.1 14.2
Agreement Index (I/U)_Post-Guidelines
I_Tot/U_Tot 1 vs 2 1 vs 3 1 vs 4 2 vs 3 2 vs 4 3 vs 4
Mean; 0.64 0.65 0.78 0.76 0.63 0.64 0.75
[min; max] [0.46; 0.75] [0.53; 0.77] [0.62; 0.86] [0.58; 0.88] [0.51; 0.77] [0.58; 0.70] [0.56; 0.88]
St. Dev 0.11 0.07 0.09 0.11 0.09 0.04 0.11
Err% 17.6 10.8 11.9 14.0 13.7 6.7 14.6
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internal process of risk analysis in RT [18]. A total of 80
contours were generated and analysed as pre-requisite to
perform the dosimetric analysis. In fact only verifying
the consistency of the contouring variability with data
reported in recent literature with higher populations isFigure 3 Isodose distributions for an example patient for (up) 3D-CRT
the introduction of guidelines. Doses are shown in colorwash ranging fr
area (red rectangle in the figure) that is differently covered by 3D-CRT and
in comparison to the 3D-CRT’s coverage.possible to perform the dosimetric analysis. In detail, AI
was calculated pre and post guidelines coupling the con-
tours of the various oncologists. The AI value increased
of about 10%, revealing a higher homogeneity in defining
the target. This result agrees with literature. Regarding
rectal cancer targets, in the study of Fuller et al. [7](low) RA optimized on PTVs defined by two physicians before
om 110% to 85% of the prescription dose. The arrows highlight an
RA. An under-dosage of the area is induced by the RA sculpting shape
Table 3 Summery of DVH analysis for PTV, bladder and
femurs
3D-PRE 3D-POST RA-PRE RA-POST p
PTVTarget
V95% [%] 99.8 ± 0.2 99.9 ± 0.1 99.7 ± 0.2 99.7 ± 0.2 -
PTV Non Target
V95% [%] 93.7 ± 9.2 96.6 ± 4.9 86.5 ± 13.8 94.5 ± 7.5 a,b,d,f
Bladder
D2% [Gy] 48.5 ± 5.1 49.0 ± 5.2 47.4 ± 3.6 46.1 ± 4.2 -
Mean [Gy] 33.4 ± 8.5 30.1 ± 6.5 32.1 ± 5.7 30.6 ± 3.8 c
D30% [Gy] 25.9 ± 5.4 18.3 ± 5.7 18.7 ± 3.3 17.6 ± 2.1 a,b,c
V40Gy [%] 20.7 ± 12.5 14.9 ± 9.5 11.9 ± 10.1 8.1 ± 5.4 a,b,c,d,e,f
Right Femur
Mean [Gy] 32.0 ± 7.5 29.9 ± 6.6 19.7 ± 4.5 18.4 ± 1.9 b,c,d,e
D2% [Gy] 41.7 ± 5.6 42.7 ± 4.7 28.2 ± 7.4 28.1 ± 3.9 b,c,d,e
Left Femur
Mean [Gy] 31.9 ± 7.0 30.2 ± 6.7 18.5 ± 4.4 20.1 ± 4.7 b,c,d,e
D2% [Gy] 41.7 ± 5.4 42.5 ± 5.3 28.7 ± 7.3 28.0 ± 6.8 b,c,d,e
The p < 0.05 for: a (3D-Pre vs 3D Post); b (3D-Pre vs RA-Pre); c (3D-Pre vs RA-
Post); d (3D Post vs Ra-Pre); e (3D-Post vs RA-Post); f (RA-Pre vs RA-Post).
Figure 4 Isodose distributions for an example patient for (up) 3D-CRT (low) RA optimized on PTVs defined by two physicians after the
introduction of guidelines. Doses are shown in colorwash ranging from 110% to 85% of prescription dose. The arrows highlight an area that is
differently covered by 3D-CRT and RA. An under-dosage of the area is induced by the RA sculpting shape in comparison to the 3D-CRT’s
coverage. To be noticed the underdosage area is lower than before the guidelines introduction.
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ation number (CN, where CN= 1 equals total agreement).
This research showed that a consensus atlas led to a
significant increase of inter-observer agreement and CN
increased from 0.58 to 0.69. Something similar was found
by Myerson et al. [5] using Kappa statistics as a measure
of agreement between participants: without any protocol
K mean value was 0.49. Comparable results were found
also for different sites. In a multi-institute study by Van
Mourick et al. [19] a conformity index (CIvm), corre-
sponding to the AI reported in this study, was determined
(per patient and per observer couple) dividing the com-
mon volume by the encompassing volume (CIvm = 0 indi-
cates no overlap between the two observers, whereas
CIvm = 1 indicates perfect overlap). CIvm value passed
from 0.3 to 0.8 with the introduction of contouring guide-
lines. This result is comparable with the one found by
Batumalai et al. [20]: using a contour reference guide for
the delineation of breast target, a mean concordance index
of 0.81 was evaluated. A similar result (mean concordance
index of 0.87) was reported by Struikmans et al. [21] for
the same site. The inter-observer concordance increasing
value, found in this research as well as in literature,
Figure 5 Cumulative histogram representing the number of plans (%) with a certain non-target PTV volume fraction covered by the
95% isodose. For example for 3D pre 83% of the plans had at least 85% of the non-target PTV volume covered by the 95% isodose.
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tribute to decrease inter-observer variability. Moreover,
the reduction of mean CTV volumes after the introduc-
tion of guidelines (649 cm3 vs 595 cm3) can be due to the
higher confidence in contouring that avoids excessively
conservative contours, for example guidelines reduced the
uncertainties regarding inclusion of external iliac nodes as
can be seen in Figures 2 and 3. This ensures a further
OAR sparing, as the irradiated volume is reduced.
Once verified the consistency of our contouring results
we focused on the evaluation of the dosimetric uncer-
tainty due to contouring observer variability for both
3DCRT and VMAT by RA techniques. Foppiano et al.
[8] investigated the impact of inter-observer variability
on rectal tumor volume and the consequences of this in
DVH analysis in order to define reliable constraints for
3D conformal RT. In our series, after the introduction of
guidelines the mean value of V95% increased for both
techniques and, at the same time, the standard deviation
decreased of about 50%. In addition, improvement in
PTV coverage was respectively of 3% for 3DCRT and of
8% for RA technique.
Moreover, dosimetric data showed the RA capability to
reliably reproduce the dosimetric quality of conventional
conformal plans, with some observable improvement such
as: treatment conformality, reduction of hot spots inside
target volume, reduction of OAR involvement like femurs
and global reduction of HT involvement. This also con-
firms that normal tissue can often be better protected with
IMRT and VMAT than with other conformal RT tech-
niques, this feature was already demonstrated by otherdosimetric investigations, in patients receiving pelvic radi-
ation for anal or rectal cancer [22-25] and other anatom-
ical regions [26-29].
While the potential of normal tissue sparing is one of
the motivations behind the move towards RA for this
site, thanks to the higher dose conformation, the identi-
fication of the correct target and the achievement of
good target coverage remain the primary objectives and
gain a still greater importance. The DVH evaluation of
non-target PTVs for all optimized plans showed possible
under dosages and hot-spots that made some plans
unacceptable. In this setting the importance of reducing
as much as possible the uncertainty in target delineation
is evident. The introduction of shared guidelines is, in
this context, a key intervention. In our study, for RA
series, more than 50% of the plans resulted in a PTV
under-dosage and this rate was reduced by more than
20% introducing guidelines. For a 3D technique this is
less crucial since the absence of modulation and dose
sculpting ensures acceptable target coverage despite the
great PTV variability. Therefore the introduction of RA
(as well as the other modulated techniques) in the clin-
ical activity requires precise target delineation as the
inverse procedure used in RA technique optimizes the
dose conformation to the contoured target.
A limitation of this study is that CT was the only im-
aging modality used to determine the tumor target.
Modern imaging techniques, such as MRI, endoscopic
ultrasound, and PET could add useful information. As
confirmed by different studies [12,30,31], the use of
PET-CT or MRI matching may reduce inter-clinician
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Another possible limitation of this study is the number
of observers used for delineation, though the optimal
number of observers required in such studies remains
unknown. The current study had a total of ten different
patients’ CT scans and four observers; this is comparable
with the study by Batumalay [20], who used four observers
and ten patients. Otherwise Fuller et al. [7] and Foppiano
et al. [8], for example, reached similar results in target
volume contouring in rectal irradiation respectively with
17 observers and 4 patients and 14 observers and only one
patient’s CT scan.
Conclusions
The introduction of guidelines reduces considerably the
inter-observer variability in neo-adjuvant rectal cancer
CTV delineation. In 3DCRT the minimization of
contouring inter-observer variability improves the dosi-
metric consistency of the plans but the low dose con-
formation makes these changes less crucial than in
modulated techniques where it is, instead, of primary
importance. The introduction of shared guidelines is
thus a necessary prerequisite when treating rectal cancer
with modulated techniques in order to avoid severe
target miss.
Abbreviations
3DCRT: 3-Dimensional RadioTherapy; AAA: Anisotropic Analytical Algorithm;
AI: Agreement Index; CT: Computed tomography; CTV: Clinical target
volume; DVH: Dose volume histogram; HT: Healthy tissue; I: Intersection;
IMRT: Intensity modulated radiotherapy; OAR: Organ at risk; PTV: Planning
target volume; RA: RapidArc; U: Union; VMAT: Volumetric modulated arc
therapy.
Competing interest
Dr. L. Cozzi is Head of Research at Oncology Institute of Southern
Switzerland and acts as a Scientific Advisor to Varian Medical Systems. The
other authors declare that they have no competing interests.
Authors’ contributions
FL, MB and PM participated in the design of the study. MB, AT, ST, FA, AG,
PN, and MS carried out the data and participated in the data evaluation. GR,
FA, AF, and LC performed the statistical analysis. FL, MB and GR drafted the
manuscript. The definitive supervision of the paper was done by MS, LC and
PM. All authors read and approved the final manuscript.
Author details
1Radiation Oncology Department, Humanitas Clinical and Research Center,
Rozzano, Milan, Italy. 2Poliambulanza Foundation Hospital, Radiation
Oncology, Brescia, Italy. 3Oncology Institute of Southern Switzerland, Medical
Physics Unit, Bellinzona, Switzerland.
Received: 12 March 2013 Accepted: 26 June 2013
Published: 9 July 2013
References
1. Kuremsky JG, Tepper JE, McLeod HL: Biomarkers for response to
neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys
2009, 74:673–688.
2. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al:
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
N Engl J Med 2004, 351:1731–1740.3. Clivio A, Fogliata A, Franzetti-Pellanda A, Nicolini G, Vanetti E, Wyttenbach R,
Cozzi L: Volumetric-modulated arc radiotherapy for carcinomas of the
anal canal: A treatment planning comparison with fixed field IMRT.
Radiother Oncol 2009, 92(1):118–124. 2009.
4. Roberton JM, Lockman D, Yan D, Wallace M: The dose volume relationship
of small bowel irradiation and acute grade 3 diarrhea during
chemoradiotherpy for rectal cancer. Int J Radiat Oncol Biol Phys 2008,
70:413–418.
5. Myerson RJ, Garofalo MC, El Naqa I, Abrams RA, Apte A, Bosch WR, et al:
Elective clinical target volumes for conformal therapy in anorectal
cancer: a radiation therapy oncology group consensus panel contouring
atlas. Int J Radiat Oncol Biol Phys 2009, 74:824–830.
6. Roels S, Duthoy W, Haustermans K, Penninckx F, Vandecaveye V, Boterberg
T, De Neve W: Definition and delineation of the clinical target volume for
rectal cancer. Int J Radiat Oncol Biol Phys 2006, 65:1129–1142.
7. Fuller CDJ, Nijkamp J, Duppen JC, Rasch CR, Thomas CR Jr, Wang SJ:
Prospective randomized double-blind pilot study of site-specific
consensus atlas implementation for rectal cancer target volume
delineation in the cooperative group setting. Int J Radiat Oncol Biol Phys
2010, 79:481–489.
8. Foppiano F, Fiorino C, Frezza G, Greco C, Valdagni R: The impact of contouring
uncertainty on rectal 3D dose-volume data: Results of a dummy run in a
multicenter trial. Int J Radiat Oncol Biol Phys 2003, 57:573–579.
9. Yorke ED, Keall P, Verhaegen F: Anniversary paper: role of medical
physicists and the AAPM in improving geometric aspects of treatment
accuracy and precision. Med Phys 2008, 35:828–839.
10. Yamazaki H, Nishiyama K, Tanaka E, Koiwai K, Shikama N, Ito Y, et al:
Dummy run for a phase II multi-institute trial if chemoradiotherapy for
unresectable pancreatic cancer: Inter-observer variance in contour
delineation,. Anticancer Res 2007, 27:2965–2971.
11. Jeanneret-Sozzi W, Moeckli R, Valley J, Zouhair A, Ozsahin EM, Mirimanoff
RO: The reasons for discrepancies in target volume delineation.
Strahlenther Onkol 2006, 182:450–457.
12. Njeh CF: Tumor delineation: The weakest link in the search for accuracy
in radiotherapy. J Med Phys 2008, 33:136–140.
13. Weiss W, Hess C: The impact of gross tumor volume (GTV) and clinical
target volume (CTV) definition on the total accuracy in radiotherapy
theoretical aspects and practical experiences. Strahlenther Onkol 2003,
179:21–30.
14. Steenbakkers RJ, Duppen JC, Fitton I, Deurloo KE, Zijp L, Uitterhoeve AL, et
al: Observer variation in target volume delineation of lung cancer
related to radiation oncologist-computer interaction: a “Big Brother”
evaluation. Radiother Oncol 2005, 77:182–190.
15. De Koste JR VS, Senan S, Underberg RW, Oei SS, Elshove D, Slotman BJ,
Lagerwaard FJ: Use of CD-ROM-based tool for analyzing contouring
variations in involved-field radiotherapy for stage III NSCLC. Int J Radiat
Oncol Biol Phys 2005, 65:334–339.
16. Oliver M, Bush K, Zavgorodni S, Ansbacher W, Beckham WA: Understanding
the impact of RapidArc therapy delivery errors for prostate cancer. J Clin
Appl Med Phys 2011, 12(3):32–43.
17. Reggiori G, Mancosu P, Tozzi A, Cantone MC, Castiglioni S, Lattuada P,
Lobefalo F, Cozzi L, Fogliata A, Navarria P, Scorsetti M: Cone beam CT pre-
and post-daily treatment for assessing geometrical and dosimetric
intrafraction variability during radiotherapy of prostate cancer. J Appl Clin
Med Phys 2010, 12(1):3371.
18. Scorsetti M, Signori C, Lattuada P, Urso G, Bignardi M, Navarria P, et al:
Applying failure mode effects and criticality analysis in radiotherapy:
Lessons learned and perspectives of enhancement. Radiother Oncol 2010,
94:367–374.
19. Van Mourik AM, Elkhuizen P, Minkema D, Duppen JC, Van Vliet-
Vroegindeweij C: Multiinstitutional study on target volume delineation
variation in breast radiotherapy in the presence of guidelines. Radiother
Oncol 2010, 94:286–291.
20. Batumalai V, Koh ES, Delaney GP, Holloway LC, Jameson MG, Papadatos G,
Lonergan DM: Interobserver variability in clinical target volume delineation
in tangential breast irradiation: a comparison between radiation
oncologists and radiation therapists. Clin Oncol 2011, 23:108–113.
21. Struikmans H, Wárlám-Rodenhuis C, Stam T, Stapper G, Tersteeg RJ, Bol GH,
Raaijmakers CP: Interobserver variability of clinical target volume
delineation of granular breast tissue and of boost volume in tangential
breast irradiation. Radiother Oncol 2005, 76:293–299.
Lobefalo et al. Radiation Oncology 2013, 8:176 Page 10 of 10
http://www.ro-journal.com/content/8/1/17622. Chen JY, Liu A, Tsai PT, Vora NL, Pezner RD, Schultheiss TE, Wong JY: Organ
sparing by conformal avoidance intensity-modulated radiation therapy
for anal cancer: dosimetric evaluation of coverage of pelvis and
inguinal/femoral nodes. Int J Radiat Oncol Biol Phys 2005, 63:274–281.
23. Duthoy W, De Gersem W, Vergote K, Boterberg T, Derie C, Smeets P, et al:
Clinical implementation of intensity-modulated arc therapy (IMAT) for
rectal cancer. Int J Radiat Oncol Biol Phys 2004, 60:794–806.
24. Guerrero Urbano MT, Henrys AJ, Adams EJ, Norman AR, Bedford JL,
Harrington KJ, et al: Intensity-modulated radiotherapy in patients with
locally advanced rectal cancer reduces volume of bowel treated to high
dose levels. Int J Radiat Oncol Biol Phys 2006, 65:907–916.
25. Menkarios C, Azria D, Laliberté B, Moscardo CL, Gourgou S, Lemanski C, et
al: Optimal organ-sparing intensity-modulated radiation therapy (IMRT)
regimen for the treatment of locally advanced anal canal carcinoma: a
comparison of conventional and IMRT plans. Radiat Oncol 2007, 2:41.
26. Scorsetti M, Mancosu P, Navarria P, Tozzi A, Castiglioni S, Clerici E, Reggiori
G, Lobefalo F, Fogliata A, Cozzi L: Stereotactic body radiation therapy
(SBRT) for adrenal metastases : a feasibility study of advanced
techniques with modulated photons and protons. Strahlenther Onkol
2011, 187(4):238–244.
27. Vieillot S, Azria D, Riou O, Moscardo CL, Dubois JB, Aillères N, Fenoglietto P:
Bilateral kidney preservation by volumetric-modulated arc therapy
(RapidArc) compared to conventional radiation therapy (3D-CRT) in
pancreatic and bile duct malignancies. Radiat Oncol 2011, 6:147.
28. Bignardi M, Cozzi L, Fogliata A, Lattuada P, Mancosu P, Navarria P, Urso G,
Vigorito S, Scorsetti M: Critical appraisal of volumetric modulated arc
therapy in stereotactic body radiation therapy for metastases to
abdominal lymph nodes. Int J Radiat Oncol Biol Phys 2009,
75(5):1570–1577.
29. Nicolini G, Ghosh-Laskar S, Shrivastava SK, Banerjee S, Chaudhary S, Agarwal
JP, Munshi A, Clivio A, Fogliata A, Mancosu P, Vanetti E, Cozzi L: Volumetric
modulation arc radiotherapy with flattening filter-free beams compared
with static gantry IMRT and 3D conformal radiotherapy for advanced
esophageal cancer: a feasibility study. Int J Radiat Oncol Biol Phys 2012,
84(2):553–560.
30. Villeirs GM, Van Vaerenbergh K, Vakaet L, Bral S, Claus F, De Neve WJ, et al:
Inter-observer delineation variation using CT versus combined CT +MRI
in intensity-modulated radiotherapy for prostate cancer. Strahlenther
Onkol 2005, 181:424–430.
31. Weltens C, Menten J, Feron M, Bellon E, Demaerel P, Maes F, et al: Inter-
observer variations in gross tumor volume delineation of brain tumors
on computed tomography and impact of magnetic resonance imaging.
Radiother Oncol 2001, 60:49–59.
doi:10.1186/1748-717X-8-176
Cite this article as: Lobefalo et al.: Dosimetric impact of inter-observer
variability for 3D conformal radiotherapy and volumetric modulated arc
therapy: the rectal tumor target definition case. Radiation Oncology
2013 8:176.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
